RxDoctor Payments Data

Shannon Weaver

Physician Assistant · Reno, NVNPI 1457903791

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.4% of the total across 396 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,389in general payments, 2019–2025

Across 396 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Astellas Pharma US Inc$715
  • GSK$487
  • Pfizer$482
  • AstraZeneca$457
  • Amgen$338
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$7,19697%
  • Education$1933%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,389 in reported general payments places this provider in the 90th percentile of 881 physician assistant providers in Nevada.

See all physician assistant providers in Nevada

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$104,621
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$79,560
Humira(Cf) PenAdalimumab12$78,058
ForteoTeriparatide13$60,280
JardianceEmpagliflozin27$44,654
EliquisApixaban42$44,046
JanuviaSitagliptin Phosphate23$31,961
XareltoRivaroxaban23$23,483
FarxigaDapagliflozin Propanediol17$20,001
TradjentaLinagliptin14$19,449
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$14,091
MyrbetriqMirabegron12$11,608
Arnuity ElliptaFluticasone Furoate22$11,300
Breo ElliptaFluticasone/Vilanterol14$9,431
EntrestoSacubitril/Valsartan12$7,932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta, Breo Ellipta$487$114,383106 claims
Novo NordiskOzempic$288$104,62162 claims
Boehringer IngelheimJardiance, Tradjenta$321$64,10341 claims
Lilly USA, LLCForteo$248$60,28013 claims
PfizerEliquis$482$44,04642 claims
MerckJanuvia$214$31,96123 claims
Johnson & JohnsonXarelto$327$23,48323 claims
AstraZenecaFarxiga$457$20,00117 claims
Astellas Pharma US IncMyrbetriq, Veozah$715$18,48723 claims
NovartisEntresto$113$7,93212 claims
AbbVieSynthroid$1,124$2,14026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 881 physician assistant providers in Nevada.

Other physician assistant in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →